Reach Us +44-1904-929220
APOC3 455 T/C Polymorphism In Metabolic Syndrome Subjects | 3606

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

APOC3 455 T/C polymorphism in metabolic syndrome subjects

3rd International Conference on Biomarkers & Clinical Research

Sudhakar Pemminati and Ashok K Shenoy

Posters: J Mol Biomark Diagn

DOI: 10.4172/2155-9929.S1.015

To identify APOC3 455 T/C polymorphism in metabolic syndrome subjects. Fifty control subjects without metabolic syndrome (MetS) and fifty patients with MetS using IDF 2005 criteria were identified. MetS was diagnosed on the presence of waist circumference (WC) (men≥ 90cm, women ≥ 80 cm) plus any two of the following four factors; (I) triglycerides (TG) >150mg/ dl (1.7mmol/l),(II) HDL-cholesterol (HDL-C) < 40 mg/dl(1.0mmol/l) for men, < 50 mg/dl(1.3mmol/l) for women, (III) fasting plasma glucose (FPG) ≥ 100mg/dl (6.1mmol/l) and (IV) blood pressure (BP) ≥ 130/85mm of Hg. Genotyping for APOC3 455 T/C polymorphism was done by polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) method. In the study group (50 patients with MetS) the wild type (normal) 455 T/T was present in 22%; the heterozygous mutant 455 C/T was present in 78%. In the control group (50 controls without MetS ) the wild type (normal) APOC3 455 T/T was present in 26%; the heterozygous mutant 455 C/T was present in 74%. (P>0.05, NS). APOC3 455 T/C polymorphism may not be a predictor of metabolic syndrome in a significant manner. Studies in larger populations and correlations with data of other studies is required.
Dr Pemminati Sudhakar has completed his Ph.D at the age of 30 years from Kasturba Medical College, Manipal University. He is the Ast Professor of Pharmacology, Kasturba Medical College, Mangalore. He has published more than 30 papers in reputed journals and serving as an editorial board member of repute. He has received two gold medals and various awards.
Relevant Topics